In the framework of the joint work of the Union “Medical and pharmaceutical projects. XXI century “, the inter-industry association PHARMPROBEG and the Organizing Committee of the Competition Regions – Sustainable Development Competition launched a program of investment projects for the pharmaceutical and medical industries * of the Russian Federation based on project financing from Sberbank Russia. “
In November 2018, at the LIFE SCIENCES INVEST. PARTNERING RUSSIA ”Dmitry Chagin, Director of the Union of Medical and Pharmaceutical Projects. XXI century “, announced the start of the development of a new specialized banking product for investment projects in the pharmaceutical and medical industries with state support or participation.
As a result of the six-month work of the attracted market experts and specialists of the “Regions – Sustainable Development” program, it was possible to create a unique banking product with special lending conditions for investment projects with state support and state participation, which has become a successful adaptation of existing developments to the conditions of the pharmaceutical industry. The product solves organizational and financial issues related to the specifics of pharmaceutical investment projects.
In particular, an organizational product was developed and introduced – an interaction scheme document that allows pharmaceutical companies to find out the conditions and terms of lending at the stage of a business idea, without requiring design estimates (PSD).
The project created a “single window” for pharmaceutical enterprises, where owners can apply for a project that is at an early stage of implementation to receive a certificate on forms of state support, as well as a positive opinion or a reasoned refusal from a credit organization of Sberbank. In this way, enterprises save resources and can improve the business idea for re-applying.
With a positive decision of the bank and the subject of state support, the company signs an investment agreement with them, which indicates the steps and responsibilities of the parties from the beginning of the development of design and estimate documentation. Information support is provided at each stage of the project. At the same time, the technical customer enters into an agreement with the general contractor, which reduces the likelihood of errors in the preparation of design and estimate documentation, as well as with the equipment supplier and engineering company, which ensures complete control and coordination of all development, construction and commissioning processes.
A banking product also takes into account the complexity of pharmaceutical projects.
- The loan term has been increased to 15 years. The standard maximum term for such projects is 8 years.
- Deferral in debt and interest – from 3 quarters to 2 years, depending on the specifics of the project instead of 1 quarter.
- Only a land plot and rights to a future property are required for a pledge, the presence of constructed objects is not required.
- The interest rate is lower than for ordinary industrial enterprises: the key rate + 1 point (instead of 3), which reduces the load on the project at the primary stage.
“I put this idea on Life Science Invest last year. Surprisingly, experts were able to quickly penetrate the specifics of our industry and create a product that not only gathered solutions to the problems voiced at the forum, but also took into account the depth and subtleties of the pharmaceutical industry processes. It is especially important that after obtaining approval from a credit institution, the decision is sent to the executive authorities of the federal subject, where these projects will be implemented. Thus, investment projects will be developed within a clear and transparent structure with the necessary support and interaction. This is a rare project that can optimize the activities of each involved party and help develop the potential of the industry, ”commented Dmitry Chagin, Director of the Union of Medical and Pharmaceutical Projects. XXI Century .
“Today in our market there are a number of trends that speak about the relevance and the need to create such a product for the pharmaceutical industry. In particular, for domestic enterprises – import substitution, for foreign companies – localization in the Russian market. In addition, we all know about the existence of a large layer of enterprises created in the Soviet era, which have an acute issue of modernization. We understand that the “Regions – Sustainable Development” program and this banking product will solve the problems of all groups of companies and massively invest in pharmaceutical production on the territory of the constituent entities of the Russian Federation, ”said Andrei Belov, head of business development at the intersectional association“ Pharmproge ” , which will oversee the industry’s Single Window.
“As in any field, the implementation of any investment project requires expert opinion. Most often, it is subjective in nature due to the sharpening of industry institutions. However, you need to look at the investment project comprehensively: existing competitors, technological solutions, legislative changes in the coming years, which may affect the implementation of the project. In the Union “Medical and pharmaceutical projects. XXI Century ”and the Pharm-Run Intersectoral Association, we found a representative who will be able to present a wide expert opinion: on the Internet platform, he accumulates knowledge, experience and information through interaction in the industry, and can give us an objective clear conclusion for each investment project and its need in the industry, ”commented Anna Belichenko, chairman of the Organizing Committee, Regions – Sustainable Development.
The “Single Window” for accepting and processing requests (investment project applications) from pharmaceutical and medical enterprises is available on the official website of the Pharm-Run interdisciplinary association at https : //pharmprobeg.ru/regiony/
* The list of the competition “Regions – Sustainable Development” included the following categories of industry facilities: laboratories; research centers; construction, modernization of pharmaceutical industries, production of medical devices, dietary supplements and cosmoseceutics; creation of retail (pharmacy) chains, networks of pharmaceutical distributors; construction, modernization of medical facilities (hospitals, clinics, medical centers, medical institutions).
